ClinConnect ClinConnect Logo
Search / Trial NCT03730636

Procalcitonin and Duration of AntiBiotherapy In Late Onset Sepsis of Neonate

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Nov 2, 2018

Trial Information

Current as of April 29, 2025

Completed

Keywords

Late Onset Sepsis (Los) Antibiotic Therapy Duration Procalcitonin (Pctr)

ClinConnect Summary

Randomized controlled multicenter open trial comparing the efficacy of PCT guided strategy (superiority aspect) and safety (non-inferiority aspect) versus usual strategy in LOS of the neonate.

After inclusion, patients are randomly assigned (in a 1:1 ratio) to duration of ATB therapy according to PCT guidance (experimental group) or to standard of care (control group).

Experimental group:

For patients randomly assigned in the PCT-guided group, a PCT concentration is measured at D0 (randomisation), at D2 and then, every two days until PCT value is equal or below 0.5 ng/mL.

The physician ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Neonates born at 24 or more weeks of gestation,
  • Aged over 96 hours of life, i.e. from the 5th day of life and less than 45 gestational weeks at diagnosis of assumed or proven LOS,
  • Weight at the inclusion ≥ 700 g,
  • Treated by ATB therapy for less than 48 hours,
  • When the physician decides to continue de empiric ATB treatment beyond the initial 48-h period,
  • Written informed consent signed by both parents (in the absence of one of the two parents the day of inclusion, the new born can be included with the signature of only one parent.The second parent must give oral consent and sign the consent form as soon as possible "before day 28"),
  • Affiliation to a social security system (recipient or assign).
  • Exclusion Criteria:
  • Neonates with non-indication of ATB treatment following the 48h-initial empiric period.
  • ATB treatment within the 48h before the current episode of infection; except for taking antibiotics for prophylactic purposes (ex: digestive decontamination), pulmonary-targeted treatments for atypical germs and antibiotics by local means (ex.: eye drops).
  • Patients diagnosed with severe infections (meningitis and/or septic shock) or needing prolonged therapy (ex: endocarditis, bone infection, deep seated infection, abscesses). Septic shock is defined by fluid resistant hypotension requiring vasopressor therapy.
  • Infections not contracted during the hospitalization in the neonatal period or revealed more than 48 hours after hospital discharge.
  • Neonates during treatment by extracorporeal membrane oxygenation or extra-corporeal circulation, and within the 72h after the end of the treatment.
  • Neonates previously included in the Proabis study.
  • Participation with another interventional study involving human subjects or being in the exclusion period at the end of a previous study involving human subjects.

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Paris, Ile De France, France

Paris, Tours, France

Patients applied

0 patients applied

Trial Officials

Delphine MITANCHEZ, PU-PH

Principal Investigator

Department of Neonatology Bretonneau Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials